Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer

NCT05900206 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

370

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Trastuzumab deruxtecan
DRUG: Docetaxel
DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Ribociclib
DRUG: Letrozole
DRUG: Epirubicin
DRUG: Cyclophosphamide

Sponsor

Karolinska University Hospital